<DOC>
	<DOCNO>NCT01174732</DOCNO>
	<brief_summary>This study randomize , active- placebo-controlled , single-dose , seven-arm , crossover dose-ranging design . This study aim evaluate efficacy initial safety profile , identify optimum dose A006 , select dose-range future clinical PK/PD Phase III study . This study conduct generally healthy , adult subject mild-to-moderate persistent asthma least 6 month prior Screening .</brief_summary>
	<brief_title>Dose-Ranging Study A006 DPI , Adult Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>With mildtomoderate persistent asthma least 6 month use inhaled betaagonist asthma control ; Must demonstrate response beta 2 agonist Reversing ; Must demonstrate ability use DPI ; Females childbearing potential must nonpregnant , nonlactating , practice clinically acceptable form birth control ; Additional Criteria Smoking history ≥ 10 packyears , smoke within 6 month ; Upper respiratory tract infection Asthma exacerbation ; Known intolerance hypersensitivity ingredient study drug Proventil® ; Use prohibit drug failure observe drug washout restriction ; Having clinical drug/device study last 30 day ; Other Criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>asthma</keyword>
	<keyword>bronchospasm</keyword>
	<keyword>COPD</keyword>
	<keyword>chronic respiratory disease</keyword>
</DOC>